Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module.
BACKGROUND
A prospective longitudinal study to profile patient-reported symptoms during radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) for head and neck cancer was performed. The goals were to understand the onset and trajectory of specific symptoms and their severity, identify clusters, and facilitate symptom interventions and clinical trial design.


METHODS
Participants in this questionnaire-based study received RT or CCRT. They completed the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module before and weekly during treatment. Symptom scores were compared between treatment groups, and hierarchical cluster analysis was used to depict clustering of symptoms at treatment end. Variables believed to predict symptom severity were assessed using a multivariate mixed model.


RESULTS
Among the 149 patients studied, the majority (47%) had oropharyngeal tumors, and nearly one-half received CCRT. Overall symptom severity (P < .001) and symptom interference (P < .0001) became progressively more severe and were more severe for those receiving CCRT. On multivariate analysis, baseline Eastern Cooperative Oncology Group performance status (P < .001) and receipt of CCRT (P < .04) correlated with higher symptom severity. Fatigue, drowsiness, lack of appetite, problem with mouth/throat mucus, and problem tasting food were more severe for those receiving CCRT. Both local and systemic symptom clusters were identified.


CONCLUSIONS
The findings from this prospective longitudinal study identified a pattern of local and systemic symptoms, symptom clusters, and symptom interference that was temporally distinct and marked by increased magnitude and a shift in individual symptom rank order during the treatment course. These inform clinicians about symptom intervention needs, and are a benchmark for future symptom intervention clinical trials.
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
David I
DI
Rosenthal
Tito R
TR
Mendoza
Clifton D
CD
Fuller
Katherine A
KA
Hutcheson
X Shelley
XS
Wang
Ehab Y
EY
Hanna
Charles
C
Lu
Adam S
AS
Garden
William H
WH
Morrison
Charles S
CS
Cleeland
G Brandon
GB
Gunn
D000328:Adult; D000368:Aged; D000855:Anorexia / Q000209:etiology; D002173:Cancer Care Facilities; D059248:Chemoradiotherapy / Q000009:adverse effects*; D017281:Cost of Illness; D005221:Fatigue / Q000209:etiology; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006785:Hospitals, University; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects*; D012720:Severity of Illness Index; D012894:Sleep Stages / Q000187:drug effects / Q000528:radiation effects; D012893:Sleep Wake Disorders / Q000209:etiology; D013280:Stomatitis / Q000209:etiology; D013315:Stress, Psychological / Q000209:etiology; D011795:Surveys and Questionnaires; D013781:Texas
chemoradiotherapy; head and neck cancer; patient-reported outcomes; radiotherapy; symptoms